BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 26214266)

  • 1. Mepolizumab versus placebo for asthma.
    Powell C; Milan SJ; Dwan K; Bax L; Walters N
    Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vilanterol and fluticasone furoate for asthma.
    Dwan K; Milan SJ; Bax L; Walters N; Powell C
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual immunotherapy for asthma.
    Fortescue R; Kew KM; Leung MST
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD011293. PubMed ID: 32926419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolides versus placebo for chronic asthma.
    Undela K; Goldsmith L; Kew KM; Ferrara G
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD002997. PubMed ID: 34807989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled corticosteroids in children with persistent asthma: effects on growth.
    Zhang L; Prietsch SO; Ducharme FM
    Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy for asthma.
    Normansell R; Kew KM; Bridgman AL
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011293. PubMed ID: 26315994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalised asthma action plans for adults with asthma.
    Gatheral TL; Rushton A; Evans DJ; Mulvaney CA; Halcovitch NR; Whiteley G; Eccles FJ; Spencer S
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011859. PubMed ID: 28394084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin C for asthma and exercise-induced bronchoconstriction.
    Milan SJ; Hart A; Wilkinson M
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010391. PubMed ID: 24154977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium versus placebo for chronic obstructive pulmonary disease.
    Karner C; Chong J; Poole P
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
    Petsky HL; Li A; Chang AB
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
    Poole P; Chong J; Cates CJ
    Cochrane Database Syst Rev; 2015 Jul; (7):CD001287. PubMed ID: 26222376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.